



WEDNESDAY 24th February 2016 COMMENCING 9.30 AM

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

	Enclosure
1. Welcome and introduction	
2. Apologies	
3. Declarations of interest	
4. Minutes of previous meeting	1/AWMSG/0216
5. Chairman's report (verbal update)	
6. Appraisal 1: Full Submission Pasireotide (Signifor[®]) for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue	2/AWMSG/0216 Appendices
7. Appraisal 2: Full Submission Ivermectin (Soolantra[®]) for the treatment of inflammatory lesions of rosacea (papulopustular) in adult patients	3/AWMSG/0216 Appendices
8. Feedback from AWPAG Meeting 16th December 2015	4/AWMSG/0216
9. Welsh Lexicon	5/AWMSG/0216
10. Advice on the Role of Oral Anticoagulants – Update	6/AWMSG/0216
11. Appraisal 3: Limited Submission Oseltamivir (Tamiflu[®]) for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms	7/AWMSG/0216 Appendices
12. Appraisal 4: Limited Submission Ustekinumab (Stelara[®]) for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies	8/AWMSG/0216 Appendices

- | | |
|---|----------------------------|
| 13. Appraisal 5: Full Submission (post independent review)
Tiotropium (Spiriva® Respimat®) indicated as add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta 2 agonists and who experienced one or more severe exacerbations in the previous year | 9/AWMSG/0216
Appendices |
|
 | |
| 14. National Prescribing Indicators (NPIs) 2016–2017 | |
| • NPIs 2016–2017 | 10/AWMSG/0216 |
| • NPIs 2016-2017 – Supporting Information for Prescribers | 11/AWMSG/0216 |
| • Secondary Care NPIs 2016–2017 | 12/AWMSG/0216 |
|
 | |
| 15. National Prescribing Indicators (NPIs) 2015–2016 – Analysis of Prescribing Data to September 2015 – for information | 13/AWMSG/0216 |

Date of next meeting: 23rd March 2016 in Cardiff